Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.
Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the potentials of both nivolumab and cabozantinib becoming first-line therapies for patients with renal cell carcinoma (RCC).
Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC. The study's primary endpoints are progression-free survival and overall survival, and the study focuses on patients with intermediate to poor risk diagnoses.
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment
November 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC
November 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.
Read More